Is Angiotensin-(1-7) legal in the United Kingdom?

The counter-regulatory arm of the renin-angiotensin system, made from angiotensin II by ACE2. It has been given to people in cancer, transplant and COVID-19 trials; the phase 1 cancer study recorded a stroke and a reversible cranial neuropathy as dose-limiting toxicities, and most of the company programme was terminated or withdrawn.

Angiotensin-(1-7) is a 7 amino acid peptide, sequence DRVYIHP, cut from angiotensin II by ACE2. It signals through the Mas receptor and opposes the vasoconstrictive, pro-fibrotic AT1 arm of the same system.

Mechanism: In humans, ACE2 converts angiotensin II to angiotensin-(1-7), which binds the Mas receptor (gene MAS1). Established human pharmacology is limited: the phase 1 study measured plasma concentrations and a fall in placental growth factor in the patients who had clinical benefit, and the phase 2 study confirmed a rise in plasma angiotensin-(1-7) 4 hours after injection but did not reproduce the biomarker change.

Regulatory history: Not approved by the FDA for any indication. Developed clinically as TXA127; no marketing application has been approved and no angiotensin-(1-7) product appeared in the 11 September 2026 Drugs@FDA checks.

Licenses medicines for the UK market. A compound without a marketing authorisation is an unlicensed medicine, which can only lawfully be supplied for human use through a prescriber under the specials scheme, not sold as a research product.

The classification above is the The Longevity Archive reading of Medicines and Healthcare products Regulatory Agency listings for Angiotensin-(1-7) at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.